Early Growth Response-1 (Egr-1), PKC Beta and Restenosis
早期生长反应-1 (Egr-1)、PKC Beta 和再狭窄
基本信息
- 批准号:6822517
- 负责人:
- 金额:$ 32.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-01 至 2008-04-30
- 项目状态:已结题
- 来源:
- 关键词:arteryblood vessel disorderblood vessel prosthesisdiabetes mellitusgel mobility shift assaygenetically modified animalsgenotypelaboratory mousemuscle cellspathologic processpolymerase chain reactionpostoperative stateprotein kinase Cprotein structure functionregulatory generestenosistranscription factorvascular endotheliumvascular smooth muscle
项目摘要
DESCRIPTION (provided by applicant): Restenosis, or recurrent lumenal narrowing, is a significant clinical problem that is especially enhanced in diabetes. With the advent of sirolimus-coated stents, the risk of restenosis after angioplasty has been strikingly reduced. Recent studies suggest the potentially powerful impact of combination therapy, such as with glycoprotein IIb/IIIa inhibitors. Therefore, it is critical to fully dissect the molecular mechanisms underlying aberrant neointimal expansion after angioplasty, as identification of new and powerful adjunctive therapies will accelerate effective therapeutic intervention strategies, particularly in diabetic subjects. Our laboratory has focused on the role of the immediate early gene, early growth response-1 (egr-1) and its key upstream regulator, PKCb, in the response to acute arterial injury. Recent observations underscored the concept that upregulation of egr-1 is linked to chronic vascular/inflammatory stress, as transcripts for egr-1 are strikingly upregulated in human and murine atherosclerotic lesions compared to adjacent non-atheromatous plaque, and after denuding arterial injury in rodents. In the vessel wall subjected to acute denuding injury in wild-type C57BL/6 mice, egr-1 is expressed rapidly after injury, particularly in smooth muscle cells (SMC) and endothelial cells (EC); in hypercholesterolemic apolipoprotein E (apo E) null (0) mice, egr-1 is also upregulated in mononuclear phagocytes (MP) infiltrating the acutely injured vessel. Our studies support a role for egr-1 and its upstream regulator, PKCBetaII in processes linked to neointimal expansion after arterial injury; mice genetically deficient in egr-1 or PKCbeta display significantly decreased neointimal expansion after femoral artery denudation injury. These considerations lead us to hypothesize that acute arterial injury results in rapid activation of PKCbetaII, thereby driving upregulation of egr-1; mechanisms linked importantly to EC, SMC, and MP activation, and modulation of neointimal expansion. We propose to dissect the mechanisms by which the PKCbetaII/egr-1 axis contributes to restenosis in vivo. To test these concepts, we will generate and characterize transgenic mice expressing functionally deficient (dominant negative, DN PKCbetaII) under the control of promoters to direct expression to EC, SMC and MP. The impact of acute denuding arterial injury in euglycemic and diabetic mice, and littermate controls will be studied. If successful, these studies will elucidate the precise cell-specific and signaling pathways by which the PKCbeta/egr-1 axis modulates the response to arterial injury and identify if these pathways are logical targets for therapeutic intervention in arterial injury.
描述(由申请人提供):复发或复发性管腔狭窄是一个重要的临床问题,尤其是在糖尿病中。随着西罗莫司涂层支架的出现,血管成形术后再狭窄的风险已显着降低。最近的研究表明,联合治疗,如与糖蛋白IIb/IIIa抑制剂的潜在强大的影响。因此,充分剖析血管成形术后异常新生内膜扩张的分子机制至关重要,因为新的有效治疗方法的确定将加速有效的治疗干预策略,特别是在糖尿病受试者中。我们的实验室一直专注于立即早期基因,早期生长反应-1(early growth response-1,ERF-1)及其关键上游调节因子PKCb在急性动脉损伤反应中的作用。最近的观察结果强调了这样的概念,即上调的α-1与慢性血管/炎症应激,因为转录的α-1是显着上调人类和小鼠动脉粥样硬化病变相比,相邻的非动脉粥样硬化斑块,并在啮齿动物剥脱动脉损伤。在野生型C57 BL/6小鼠急性剥脱性损伤的血管壁中,损伤后,尤其是在平滑肌细胞(SMC)和内皮细胞(EC)中,β-1迅速表达;在高胆固醇血症载脂蛋白E(apo E)null(0)小鼠中,β-1在浸润急性损伤血管的单核吞噬细胞(MP)中也上调。我们的研究支持β-1及其上游调节因子PKC β II在动脉损伤后新生内膜扩张相关过程中的作用; β-1或PKC β基因缺陷的小鼠在股动脉剥脱损伤后新生内膜扩张显著减少。这些考虑使我们假设急性动脉损伤导致PKC β II的快速激活,从而驱动PKC-1的上调;与EC、SMC和MP激活以及调节新生内膜扩张重要相关的机制。我们建议剖析PKC β II/PKC β 1轴导致体内再狭窄的机制。为了测试这些概念,我们将产生和表征在启动子控制下表达功能缺陷(显性阴性,DN PKCbetaII)的转基因小鼠,以指导EC、SMC和MP的表达。将研究急性剥脱性动脉损伤对血糖正常和糖尿病小鼠以及同窝对照小鼠的影响。如果成功,这些研究将阐明PKC β/β 1轴调节动脉损伤反应的精确细胞特异性和信号传导途径,并确定这些途径是否是动脉损伤治疗干预的逻辑靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHI FANG YAN其他文献
SHI FANG YAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHI FANG YAN', 18)}}的其他基金
RAGE, mitochondria, and tau pathology in AD
AD 中的 RAGE、线粒体和 tau 病理学
- 批准号:
10532703 - 财政年份:2019
- 资助金额:
$ 32.7万 - 项目类别:
RAGE, mitochondria, and tau pathology in AD
AD 中的 RAGE、线粒体和 tau 病理学
- 批准号:
10320076 - 财政年份:2019
- 资助金额:
$ 32.7万 - 项目类别:
PINK1 signaling and synaptic mitochondria integrity in AD
AD 中的 PINK1 信号传导和突触线粒体完整性
- 批准号:
10091121 - 财政年份:2018
- 资助金额:
$ 32.7万 - 项目类别:
Egr-1, PKC Beta, Signalling and Atherosclerosis
Egr-1、PKC Beta、信号传导和动脉粥样硬化
- 批准号:
7162602 - 财政年份:2005
- 资助金额:
$ 32.7万 - 项目类别:
Egr-1, PKC Beta, Signalling and Atherosclerosis
Egr-1、PKC Beta、信号传导和动脉粥样硬化
- 批准号:
7330488 - 财政年份:2005
- 资助金额:
$ 32.7万 - 项目类别:
Egr-1, PKC Beta, Signalling and Atherosclerosis
Egr-1、PKC Beta、信号传导和动脉粥样硬化
- 批准号:
7006966 - 财政年份:2005
- 资助金额:
$ 32.7万 - 项目类别:
Egr-1, PKC Beta, Signalling and Atherosclerosis
Egr-1、PKC Beta、信号传导和动脉粥样硬化
- 批准号:
6867116 - 财政年份:2005
- 资助金额:
$ 32.7万 - 项目类别:
Egr-1, PKC Beta, Signalling and Atherosclerosis
Egr-1、PKC Beta、信号传导和动脉粥样硬化
- 批准号:
7568212 - 财政年份:2005
- 资助金额:
$ 32.7万 - 项目类别:
Early Growth Response-1 (Egr-1), PKC Beta and Restenosis
早期生长反应-1 (Egr-1)、PKC Beta 和再狭窄
- 批准号:
7078584 - 财政年份:2004
- 资助金额:
$ 32.7万 - 项目类别:
Early Growth Response-1 (Egr-1), PKC Beta and Restenosis
早期生长反应-1 (Egr-1)、PKC Beta 和再狭窄
- 批准号:
6894666 - 财政年份:2004
- 资助金额:
$ 32.7万 - 项目类别: